ArticleJournal of clinical and experimental hepatology
Spleen Area Affects the Performance of the Platelet Count-Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease Cirrhosis.
Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence prognostication of liver disease using imaging.The British journal of radiology · 2026Review
- Machine learning-based prediction models for liver-related events in patients with hepatitis B-related cirrhosis and clinically significant portal hypertension.World journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Various non-invasive tools (NITs) predicting first hepatic decompensation (HD) in advanced chronic liver disease (ACLD) enclose platelet (PLT) count. A relevant proportion of metabolic dysfunction-associated steatotic liver disease (MASLD)-ACLD patients do not show splenomegaly- and hypersplenism-related thrombocytopenia. We aimed to evaluate the performance of NITs in predicting HD according to ultrasound-assessed spleen size. Methods: In this observational study, 148 splenic and 27 asplenic (ASP) MASLD-compensated advanced chronic liver disease (cACLD) patients were enrolled. Ultrasound artificial intelligence-based tools distinguished splenomegaly-affected patients (SAPs) and normal-spleen patients (NSPs). Albumin-Bilirubin score (ALBI) and PLT count-based NITs (PLNs) (Fbrosis-4 [FIB-4], ALBI-FIB-4, red cell distribution width-to-PLT ratio [RPR], liver stiffness measurement [LSM]-to-platelet ratio [LSM/PLTr], and ANTICIPATE ± non-alcoholic steatohepatitis [NASH]) were determined. Over 3 years, the first HD was recorded. Results: Limitedly to SAP, spleen area inversely correlated with PLT (relationship [R]: -0.981; Conclusion: Ultrasound-assessed spleen size affects the predictive performance of the PLNs in MASLD-cACLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.